New hope for rare digestive tumors: drug trial targets stubborn cancers
NCT ID NCT03891784
First seen Jan 16, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests a drug called abemaciclib in 20 people with advanced digestive neuroendocrine tumors that have stopped responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if it can shrink or slow the tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
University of Colorado
Denver, Colorado, 80217, United States
Conditions
Explore the condition pages connected to this study.